PHILADELPHIA – United States Attorney William M. McSwain
announced today that pharmaceutical company Mallinckrodt ARD LLC (formerly
known as Mallinckrodt ARD, Inc. and previously Questcor Pharmaceuticals, Inc.
(“Questcor”)), has agreed to pay $15.4 million to resolve claims that Questcor
paid illegal kickbacks to doctors from 2009 through 2013 in the form of lavish
dinners and entertainment, to induce prescriptions of the company’s drug, H.P.
Acthar Gel (“Acthar”) for the treatment of complications from multiple
sclerosis.
The Federal Anti-Kickback Statute prohibits a pharmaceutical
company from offering or paying, directly or indirectly, any remuneration—which
includes money or any other thing of value—with the intent to induce a health
care provider to prescribe a drug reimbursed by Medicare. This prohibition
extends to such practices as “wining and dining” doctors to induce them to
write Medicare prescriptions of a company’s products.
The government alleges that, from 2009 to 2013, twelve
Questcor sales representatives marketing Acthar provided illegal remuneration
to health care providers in the form of lavish meals and entertainment
expenses. The company paid this remuneration, the government alleges, with the
intent to induce Acthar Medicare referrals from those health care providers,
resulting in a violation of the Anti-Kickback Statute and the submission of
false claims to Medicare.
“Federal law protects patients from medical providers who
write prescriptions so they can enrich themselves and from drug companies who
do not play by the rules in their marketing and promotional efforts,” said U.S.
Attorney McSwain. “Kickback schemes are a form of illegal pay-to-play business
practices that have no place in our health care system; they interfere with
physician-patient relationships and drive up the cost of health care.”
“The Department of Justice will hold companies accountable
for the payment of illegal kickbacks in any form,” said Assistant Attorney
General Jody Hunt of the Department of Justice’s Civil Division. “Improper
inducements have no place in our federal healthcare system, which depends on
physicians making decisions based on the healthcare needs of their patients and
not on or influenced by personal financial considerations.”
“Paying kickbacks to win business, as contended in this case,
cheats taxpayers and the patients who rely on government health care programs
for essential care,” said Maureen R. Dixon, Special Agent in Charge for the
Office of Inspector General of the U.S. Department of Health and Human
Services. “We will continue working with our law enforcement partners to hold
accountable entities paying such kickbacks.”
The allegations relevant to this settlement were originally
alleged in two cases filed under the whistleblower, or qui tam, provision of
the False Claims Act. The act permits private parties to sue for fraud on
behalf of the United States and to share in any recovery. The act also permits
the government to intervene in such actions, as the government previously did
in the two whistleblower cases, which are captioned United States of America ex
rel. Strunck et al. v. Mallinckrodt ARD, Inc., No. 12-CV-0175 (E.D. Pa.), and
United States of America ex rel. Clark v. Questor Pharmaceuticals, Inc., No.
13-CV-1776 (E.D. Pa.). The government’s pursuit of these matters illustrates
its emphasis on combating healthcare fraud. One of the most powerful tools in
this effort is the False Claims Act. Tips and complaints from all sources about
potential fraud, waste, abuse, and mismanagement can be reported to the
Department of Health and Human Services, at 800 HHS TIPS (800-447-8477). The
whistleblowers will receive approximately $2.926 million of the settlement.
This matter is being handled by the Civil Division of the
U.S. Attorney’s Office for the Eastern District of Pennsylvania and the
Department of Justice’s Commercial Litigation Branch, with assistance from the
U.S. Department of Health and Human Services’ Office of Inspector General, the
Defense Criminal Investigative Service, the Federal Bureau of Investigation and
the Office of Personnel Management. For the United States Attorney’s Office,
the matter is being handled by Assistant United States Attorney Colin Cherico
and Auditor George Niedzwicki.
The claims resolved by settlement are allegations only and
there has been no determination of liability.
No comments:
Post a Comment